Cardiovascular Drugs Market to Reach New Heights by 2030, Driven by Rising Disease Prevalence and Innovation

▤ Summary

This report says the global cardiovascular drugs market should keep growing through 2030 as cardiovascular disease prevalence rises worldwide. It highlights North America as the largest market and points to APAC growth driven by government programs and venture capital investment. The report also emphasizes innovation in siRNA-based therapies, SGLT2 inhibitors, and other next-generation treatments that are reshaping the competitive landscape. Major pharmaceutical companies are increasing R&D spending, licensing activity, and marketing to defend share and capture new revenue. The article is relevant as a market intelligence update, but it does not describe a discrete company event.

▦ Linked Companies